Posted on 7/16/18
Court Ruling in Favor of Aquestive Therapeutics Enjoining Dr. Reddy's Laboratories from Launching its Generic Suboxone Product
Aquestive Therapeutics announces today that the U.S. District Court for the District of New Jersey has granted Aquestive together with Indivior PLC (LON: INDV) and its U.S. . . .
Posted on 7/16/18
Cognizant Leads the Pack in Life Sciences Digital Services According to New Everest Group Assessment
Cognizant has been named one of the top providers of digital services for life sciences organizations in a new PEAK Matrix report by consulting and research . . .
Posted on 7/16/18
Better Buy: Amgen Inc. vs. Johnson & Johnson
It's a big drugmaker with a blockbuster immunology drug as its top-selling product. It pays an attractive dividend. And it faces some uncertainties. This description fits . . .
Posted on 7/16/18
Here's Why Cara Therapeutics Jumped 56.5% in the First Half of 2018
What happenedShares of Cara Therapeutics (NASDAQ:CARA), a clinical-stage biotech developing novel pain-management drugs, soared 56.5% during the first half of 2018, according to data from S&P . . .
Posted on 7/16/18
Pfizer Is Not An All-Powerful Price-Hiker
For a supposedly greedy, all-powerful, price-hiking Big Pharma megacap, Pfizer's (PFE) stock sure isn't doing too well over the long term. There seems to be this . . .
Posted on 7/16/18
Johnson & Johnson Is Recovering From Talcum Powder Correction, Faces Earnings
Johnson & Johnson (NYSE:JNJ) is an iconic and diverse health care giant and a component of the Dow Jones Industrial Average. The stock is down 9.9% . . .
Posted on 7/16/18
Johnson & Johnson: Floodgates And Tidal Waves
Watching an 80-foot wave break at Nazaré, Portugal. (via YouTube).Tidal Waves And FloodgatesLast August, the Financial Times warned that a "tidal wave" of opioid-related lawsuits was . . .
Posted on 7/16/18
Why Celgene Corporation Lost 23.9% of Its Value Halfway Through 2018
What happenedShares of blue-chip biotech Celgene Corporation (NASDAQ:CELG) fell by a staggering 23.9% through the first six months of this year, according to data from S&P . . .
Posted on 7/16/18
Synergy Pharmaceuticals: Partner, Merger, Ex-USA Deal Or Co-Promotion?
Investors in Synergy Pharmaceuticals (SGYP) should be encouraged that the first roots of a turnaround are beginning to show in the stock. At least it seems . . .
Posted on 7/13/18
J&J Slammed With $4.69B Jury Verdict In Missouri Cancer Case
The Missouri jury that awarded $550M to 22 women and their families who blamed ovarian cancer cases on asbestos in Johnson & Johnson's (NYSE:JNJ) talc-based products . . .
Posted on 7/13/18
Why Johnson & Johnson Stock Has Lost 13% So Far in 2018
What happenedShares of healthcare titan Johnson & Johnson (NYSE:JNJ) trailed the market through the first six months of 2018 by shedding 13%, compared to a 2% . . .
Posted on 7/13/18
Antoxerene Closes $10 Million Deal with Juvenescence
LAFAYETTE, N.Y.--(BUSINESS WIRE)--Antoxerene, Inc., a portfolio company of Ichor Therapeutics, Inc., focused on small molecule drug discovery for pathways of aging, announced today the launch of . . .
Posted on 7/12/18
Navitas Life Sciences Named as a Leader in IDC MarketScape
Navitas Life Sciences, a wholly owned subsidiary of TAKE Solutions and a full service Clinical, Regulatory & Safety solutions and services provider today announced that it . . .
Posted on 7/12/18
Aquestive Therapeutics Files For $69 Million U.S. IPO
Quick TakeAquestive Therapeutics (AQST) intends to raise gross proceeds of $69 million from a U.S. IPO, according to an S-1 registration statement.The firm is a specialty . . .
Posted on 7/12/18
4 Things You Need to Know About Pfizer's Restructuring Plans
Pfizer (NYSE:PFE) was in the news Wednesday for a second day in a row. On Tuesday, the company announced that it was holding off on price . . .
Posted on 7/12/18
Blink Health Partners with Blue Eagle Health
NEW YORK--(BUSINESS WIRE)--Blink Health, the e-commerce platform that makes prescription drugs affordable for everyone, announces that it will guarantee the lowest prices for generic prescriptions through . . .
Posted on 7/11/18
Bioasis and BioAgilytix Announce Strategic Collaboration
RICHMOND, British Columbia & GUILFORD, Conn. & DURHAM, N.C.--(BUSINESS WIRE)--BIOASIS TECHNOLOGIES INC. (TSX.V:BTI; OTCQB:BIOAF), a biopharmaceutical company developing its xB3 TM proprietary platform technology for the . . .
Posted on 7/11/18
Celgene: Fears Are Overplayed
Any company buying back a lot of stock always catches my attention. A stock has to be cheap and the balance sheet strong in order for . . .
Posted on 7/11/18
H1 Announces Continued Growth and Expansion of Healthcare Machine Learning Analytics Platforms
H1, a New York-based healthcare data-driven solutions provider, today announced continued growth and expansion of its global healthcare analytics platforms marked by strong top-line revenue growth.In the past year, H1 has grown . . .
Posted on 7/10/18
Roivant Sciences Provides Corporate Updates
Roivant Sciences announced a series of corporate updates across the Roivant family of companies in advance of its first annual Pipeline Day this afternoon in New . . .
Posted on 7/10/18
Why CTI BioPharma, PetMed Express, and Pfizer Slumped Today
Major market benchmarks extended Friday's gains on Monday, as investors ignored continued trade tensions to instead look forward to the start of a potentially strong corporate . . .
Posted on 7/10/18
Achillion Pharmaceuticals - Biotech Gold For The Price Of Dirt
Welcome to Achillion Pharmaceuticals (NASDAQ:ACHN). I've been following the company for a bit, but only after the Johnson & Johnson (NYSE:JNJ) Hep C disaster, so I . . .
Posted on 7/10/18
Nasdaq Notifies PAVmed of Regained Compliance with Continued Listing Requirements
NEW YORK--(BUSINESS WIRE)--PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced that The Nasdaq Stock Market LLC . . .
Posted on 7/9/18
NIH and Matinas BioPharma Announce Research Collaboration
BEDMINSTER, N.J. and WASHINGTON, July 09, 2018 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER:MTNB), a clinical-stage biopharmaceutical company focused on developing innovative medicines using . . .
Posted on 7/9/18
Citius Provides Clinical Update And Progress Of The Mino-Lok Phase 3 Trial
Citius Pharmaceuticals, Inc. (NASDAQ: CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, provided a status report on the progress . . .

